Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TME111
- Development stage
- Preclinical
- Lead developer
- TME Therapeutics
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral
01
Overview
TME111 is a double-stranded RNA (dsRNA) oligonucleotide therapeutic being developed by TME Therapeutics for the treatment of non-alcoholic steatohepatitis (NASH). It is designed to target and knockdown the expression of Carbohydrate sulfotransferase 11 (CHST11), an enzyme that plays a critical role in the biosynthesis of chondroitin sulfate and the remodeling of the extracellular matrix. CHST11 expression is associated with the progression of liver fibrosis and inflammation, which are hallmark features of NASH. By utilizing an RNA interference (RNAi) mechanism to reduce CHST11 levels, TME111 aims to halt or reverse fibrotic changes in the liver. The drug is currently in the preclinical stage of development.
02
Targets
Glycosylation (Glycosylation enzymes)
Beyond the preview
Go deeper on TME111.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TME111.